Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (237)	8/3/1998 1:11:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 340

Honestly, Doug, I have no idea what earnings will be. In the case of Teva, I defer to the analysts. Paine Webber and GS have been most accurate in their biotech/pharm earnings predictions: maybe someone can post what those companies anticipate for earnings. I went to the Biogen annual meeting and was surprised to see Teva's COP-1 had 18% of the expanding MS market. That was something unexpected. There are roughly 70,000 patients on treatment in the US and a good sized European market as well. COP-1 is statistically much inferior to the beta interferons on the market and has some side-effects - but, there it was, 18% and growing at Schering's expense. So, I expect COP-1 to add to Teva's earnings this year and think it was pretty well discounted after a slow launch. Don't know much about Teva, but the numbers are pretty compelling at this stock price. Be surprised if it doesn't show up on a lot of trading screens as a cheap buy. Again, if Teva can come close the growth rates projected by analysts, it should move significantly upward. All the best, Harold